Cargando…

Cabozantinib for HCC Treatment, From Clinical Back to Experimental Models

Hepatocellular carcinoma (HCC) is the fourth leading cause of cancer-related mortality worldwide. Patients with early-stage HCC can be treated successfully with surgical resection or liver transplantation. However, the usual late diagnosis of HCC precludes curative treatments, and systemic therapies...

Descripción completa

Detalles Bibliográficos
Autores principales:	Deng, Shanshan, Solinas, Antonio, Calvisi, Diego F.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8548824/ https://www.ncbi.nlm.nih.gov/pubmed/34722310 http://dx.doi.org/10.3389/fonc.2021.756672

Ejemplares similares

Cabozantinib-based combination therapy for the treatment of hepatocellular carcinoma
por: Shang, Runze, et al.
Publicado: (2021)

Immunogenic Cell Death and Immunomodulatory Effects of Cabozantinib
por: Scirocchi, Fabio, et al.
Publicado: (2021)

Immune Checkpoint Inhibitors in the Treatment of HCC
por: Donisi, Clelia, et al.
Publicado: (2021)

Metastatic mesenchymal chondrosarcoma showing a sustained response to cabozantinib: A case report
por: Blum, Veronika, et al.
Publicado: (2022)

Study on the changes of CT texture parameters before and after HCC treatment in the efficacy evaluation and survival predication of patients with HCC
por: Zhou, Wei, et al.
Publicado: (2022)

Tyrosine Kinase Inhibitor Cabozantinib Inhibits Murine Renal Cancer by Activating Innate and Adaptive Immunity
por: Liu, Hongyan, et al.
Publicado: (2021)

Cabozantinib sensitizes microsatellite stable colorectal cancer to immune checkpoint blockade by immune modulation in human immune system mouse models
por: Lang, Julie, et al.
Publicado: (2022)

A Combination of Cabozantinib and Radiation Does Not Lead to an Improved Growth Control of Tumors in a Preclinical 4T1 Breast Cancer Model
por: Reppingen, Norman, et al.
Publicado: (2021)

Splenic Volume, an Easy-To-Use Predictor of HCC Late Recurrence for HCC Patients After Hepatectomy
por: Fang, Tongdi, et al.
Publicado: (2022)

SLC1A4: A Powerful Prognostic Marker and Promising Therapeutic Target for HCC
por: Peng, Xiaozhen, et al.
Publicado: (2021)

Cell-Free DNA Profiling to Discover Mechanisms of Exceptional Response to Cabozantinib Plus Panitumumab in a Patient With Treatment Refractory Metastatic Colorectal Cancer
por: Jia, Jingquan, et al.
Publicado: (2018)

Cabozantinib (XL184) and R428 (BGB324) Inhibit the Growth of Esophageal Squamous Cell Carcinoma (ESCC)
por: Yang, Pei-Wen, et al.
Publicado: (2019)

Atractylenolide I inhibits EMT and enhances the antitumor effect of cabozantinib in prostate cancer via targeting Hsp27
por: Qiao, Pengfei, et al.
Publicado: (2023)

Upregulation of Serum Sphingosine (d18:1)-1-P Potentially Contributes to Distinguish HCC Including AFP-Negative HCC From Cirrhosis
por: Jiang, Yingying, et al.
Publicado: (2020)

Validation of the GALAD model and establishment of a new model for HCC detection in Chinese patients
por: Chen, Ping, et al.
Publicado: (2022)

Case Report: Exceptional response to nivolumab plus cabozantinib in a patient with extrarenal clear cell renal cell carcinoma
por: Jansen, Caroline S., et al.
Publicado: (2023)

Development of cabozantinib for the treatment of prostate cancer
por: Vaishampayan, Ulka N
Publicado: (2014)

Corrigendum: Validation of the GALAD model and establishment of a new model for HCC detection in Chinese patients
por: Chen, Ping, et al.
Publicado: (2023)

Impressive reduction of brain metastasis radionecrosis after cabozantinib therapy in metastatic renal carcinoma: A case report and review of the literature
por: Lolli, Jacopo, et al.
Publicado: (2023)

A novel HCC prognosis predictor PDSS1 affects the cell cycle through the STAT3 signaling pathway in HCC
por: Rao, Zuqin, et al.
Publicado: (2022)

Neoadjuvant Cabozantinib in an Unresectable Locally Advanced Renal Cell Carcinoma Patient Leads to Downsizing of Tumor Enabling Surgical Resection: A Case Report
por: Bilen, Mehmet A., et al.
Publicado: (2021)

US-Based Deep Learning Model for Differentiating Hepatocellular Carcinoma (HCC) From Other Malignancy in Cirrhotic Patients
por: Zhou, Hang, et al.
Publicado: (2021)

Pathogenetic, Prognostic, and Therapeutic Role of Fatty Acid Synthase in Human Hepatocellular Carcinoma
por: Che, Li, et al.
Publicado: (2019)

Corrigendum: Pathogenetic, Prognostic, and Therapeutic Role of Fatty Acid Synthase in Human Hepatocellular Carcinoma
por: Che, Li, et al.
Publicado: (2022)

Corrigendum: Impressive reduction of brain metastasis radionecrosis after cabozantinib therapy in metastatic renal carcinoma: a case report and review of the literature
por: Lolli, Jacopo, et al.
Publicado: (2023)

HCC biomarkers – state of the old and outlook to future promising biomarkers and their potential in everyday clinical practice
por: Schlosser, Sophie, et al.
Publicado: (2022)

Regorafenib combined with sintilimab as second-line treatment for advanced HCC patient: a case report
por: Wan, Yanzhi, et al.
Publicado: (2023)

A case of cabozantinib therapy leading to complete remission for massive intra-intestinal bleeding and worsening metastatic sites following nivolumab and ipilimumab therapy
por: Ishida, Kyohei, et al.
Publicado: (2023)

Regression of Intracranial Meningiomas Following Treatment with Cabozantinib
por: Kotecha, Rupesh, et al.
Publicado: (2021)

Development of cabozantinib for the treatment of prostate cancer [Corrigendum]
Publicado: (2014)

Cabozantinib for the Treatment of Metastatic Medullary Thyroid Carcinoma
por: Nix, Nancy M., et al.
Publicado: (2014)

Kill and Clearance in HCC: An Approach Based on NK Cells and Macrophages
por: Mehrabi, Maryam, et al.
Publicado: (2021)

Epigenetic Mechanisms Involved in HCV-Induced Hepatocellular Carcinoma (HCC)
por: Zhao, Pin, et al.
Publicado: (2021)

Evaluation of D-TACE combined with endovascular brachytherapy for HCC with MPVTT
por: Huang, Wei, et al.
Publicado: (2022)

Hsa-miR-4277 Decelerates the Metabolism or Clearance of Sorafenib in HCC Cells and Enhances the Sensitivity of HCC Cells to Sorafenib by Targeting cyp3a4
por: He, Xi, et al.
Publicado: (2021)

HCC and Molecular Targeting Therapies: Back to the Future
por: Rinaldi, Luca, et al.
Publicado: (2021)

EGFR blockade confers sensitivity to cabozantinib in hepatocellular carcinoma
por: Ma, Xuhui, et al.
Publicado: (2022)

Roles of lncRNAs Mediating Wnt/β-Catenin Signaling in HCC
por: Xu, Yating, et al.
Publicado: (2022)

Targeting mitochondrial quality control of T cells: Regulating the immune response in HCC
por: Xia, Yixue, et al.
Publicado: (2022)

A key driver to promote HCC: Cellular crosstalk in tumor microenvironment
por: Liu, Pengyue, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_4njhegdismhenb49g3kng01mld